Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Apr 06, 2021	Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti® New patent expands intellectual property protection for nasal delivery of metoclopramide SOLANA BEACH, Calif. , April 06, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the	View HTML PDF Version
Toggle Summary Jul 26, 2016	Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001 SOLANA BEACH, Calif., July 26, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the US Food and Drug Administration (FDA) has conditionally accepted the proprietary brand	View HTML Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001 14.7 KB
Toggle Summary Apr 02, 2019	Evoke Pharma Receives Complete Response Letter and Recommendations to Address Deficiencies from FDA for Gimoti™ NDA SOLANA BEACH, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S.	View HTML PDF Version
Toggle Summary May 10, 2017	Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017 Data Demonstrate Gimoti Significantly Improves Symptoms in Women with Moderate to Severe Diabetic Gastroparesis	View HTML Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017 22.3 KB
Toggle Summary May 24, 2016	Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 Further Safety of EVK-001 Demonstrated with TQT Results	View HTML Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 16.5 KB
Toggle Summary Feb 02, 2015	Evoke Pharma Outlines Progress on Clinical Program SOLANA BEACH, Calif. , Feb. 2, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today provided an update on its clinical program for EVK-001, its novel metoclopramide nasal spray for the relief of	View HTML Evoke Pharma Outlines Progress on Clinical Program 16.3 KB
Toggle Summary Jul 14, 2021	Evoke Pharma Launches Gimoti® Patient and Physician Experience Program Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers SOLANA BEACH, Calif. , July 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced	View HTML PDF Version
Toggle Summary Apr 22, 2014	Evoke Pharma Initiates Phase 3 Clinical Trial of EVK-001 for Treatment of Gastroparesis First Patient Enrolled in Study of Novel Intranasal Formulation and Delivery of Metoclopramide	View HTML Evoke Pharma Initiates Phase 3 Clinical Trial of EVK-001 for Treatment of Gastroparesis 16.8 KB
Toggle Summary Aug 14, 2017	Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti™ Expected to be final clinical trial prior to 505(b)(2) NDA submission	View HTML Evoke Pharma Initiates Comparative Exposure Pharmacokinetic Study for Gimoti™ 35 KB
Toggle Summary Jul 15, 2020	Evoke Pharma Initiates Commercial Manufacturing of Gimoti™ Preparing commercial launch of GIMOTI™ in 4Q 2020 SOLANA BEACH, Calif. , July 15, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has initiated the commercial	View HTML PDF Version